Since the increase of TA-HEVs relies on Fc-dependent mechanisms during anti-CTLA-4 therapy, we next examined how an Fc-enhanced version of 9D9 (mouse IgG2a Fc, Figure S8A) would modulate tumor-infiltrating CD4+ T cells and TA-HEVs. This evidence concerns the gene CTLA4 and neoplasm.